Frederick L. Ruberg, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Dept of Medicine
Cardiovascular Medicine

MD, University of Pennsylvania School of Medicine

Pronouns: he/him/his



Dr. Ruberg's clinical and research expertise is in the field of cardiac imaging including echocardiography and cardiovascular magnetic resonance imaging (CMR). Dr. Ruberg applies imaging in research designed to facilitate improved diagnosis and management of the infiltrative cardiomyopathy cardiac amyloidosis.

Diversity, Equity, Inclusion and Accessibility

I am deeply committed to developing an equitable and supportive clinical and research environment at BU/BMC. Through my nearly 2 decades of experience and leadership at BU/BMC, I have been focused on increasing representation of women and under-represented minority groups in medicine (URiM) in the clinical workforce while working to ensure that such populations are appropriately represented in research programs. Under my leadership as Program Director of the clinical fellowship training program and now Associate Chief of Cardiovascular Medicine, the cardiovascular medicine fellowship has achieved an approximate 50% women trainee census, and presently exceeds national census means for trainees who identify as URiM in cardiovascular medicine. I also serve as the Section lead of the BUMG campus-wide Commitment to Operationalize Racial Equity (CORE) program (to define and meet racial equity goals) and served as a member of the Department of Medicine Faculty Development and Diversity Committee before transitioning to my current position on the BUMG Women’s Leadership Advisory Council. My current clinical research team reflects this commitment, composed nearly entirely of women and/or URiM trainees. My primary research focus, hereditary transthyretin cardiac amyloidosis (ATTR), is a heart disease that disproportionately affects patients identifying as Black. I have served as PI on two awards from NIH that specifically focus on ATTR cardiac amyloidosis (most notably the ongoing Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations, or SCAN-MP study). Finally, since 2016, I have also meaningfully contributed to development of a diverse scientific workforce at BU by facilitating the careers of early investigators through my role as Director of Pilot Grant Award Program at the BU Clinical and Translational Science Institute.

Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Radiology


Member
Boston University
Whitaker Cardiovascular Institute


Member
Boston University
Amyloidosis Center


Program Director
Boston University Chobanian & Avedisian School of Medicine
Clinical and Translational Science Institute
Pilot Translational & Clinical Studies Program



Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Subcontract PI)
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-04


Gadolinium-Free Myocardial Scar and Fibrosis Imaging with Ca
07/01/2020 - 06/30/2024 (PI)
Beth Israel Deaconess Medical Center National Heart, Lung

Scan-MP (Screening fro cardiac amyloidosis with nuclear imag
05/01/2019 - 02/29/2024 (PI)
The Trustees of Colombia University in the City of New York dba Colombia University National Heart, Lung

Screening for ATTR Amyloidosis among patients undergoing lumbar spinal stenosis decompression…
02/11/2020 - 02/11/2023 (PI)
Akcea Therapeutics, Inc

2020 RD L – Cardiac Amyloidosis Fellowship U.S
10/26/2020 - 10/25/2022 (PI)
Pfizer, Inc

2021 Transthyretin Cardiac Amyloidosis Fellowship
10/14/2021 - 10/13/2022 (PI)
Pfizer, Inc

Alnylam - MGH study agreement (2019A017487)
09/01/2020 - 08/31/2022 (PI)
Massachusetts General Hospital Alnylam Pharmaceutic

SCAN-MP Supplement SCREENING FOR CARDIAC AMYLOIDOSIS WITH NUCLEAR IMAGING IN MINORITY POPULATIONS (SCAN-MP) STUDY
09/01/2020 - 08/31/2022 (PI)
Trustees of Columbia University National Heart, Lung

Longitudinal strain in ATTR cardiac amyloidosis
09/25/2017 - 09/25/2021 (PI)
Eidos Therapeutics

Cardiac Amyloidosis Fellowship
01/01/2019 - 07/01/2021 (PI)
Pfizer, Inc

2019 US ASPIRE for TTR Amyloidosis
09/23/2019 - 06/03/2021 (PI)
Tufts Medical Center Pfizer, Inc

Showing 10 of 17 results. Show All Results

Title

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Rowin EJ, Ruberg FL, Das G, Higgins D, Lipe WC, Bokhari N, Dehn M, Maron BJ, Maron MS. Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2022 Dec; 15(12):e014938. PMID: 36448453; DOI: 10.1161/CIRCIMAGING.122.014938;
     
  2. Cuddy SA, Datar Y, Ovsak G, Saith S, Murphy SP, Bay CP, Haddad M, Lilleness B, Muralidhar V, Pipilas A, Vuong J, Guardino E, Maurer MS, Ruberg FL, Falk RH, Dorbala S. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2022 Nov; 15(11):e014645. PMID: 36378779; PMCID: PMC9667717; DOI: 10.1161/CIRCIMAGING.122.014645;
     
  3. Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Grogan M, Witteles R, Ruberg FL, Maurer MS, Tran N, Qin X, Vasey SY, Weiss BM, Vermeulen J, Jaccard A. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. JACC CardioOncol. 2022 Nov; 4(4):474-487. PMID: 36444227; PMCID: PMC9700253; DOI: 10.1016/j.jaccao.2022.08.011;
     
  4. Alreshq R, Cozzolino M, Lilleness B, Pipilas A, Mendelson L, Joshi T, Muralidhar V, Guardino E, Berk JL, Siddiqi OK, Gopal DM, Sanchorawala V, Ruberg FL. Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. Am J Cardiol. 2022 Oct 15; 181:105-112. PMID: 36028388; PMCID: PMC9675982; DOI: 10.1016/j.amjcard.2022.06.064;
     
  5. Tahir UA, Katz DH, Avila-Pachecho J, Bick AG, Pampana A, Robbins JM, Yu Z, Chen ZZ, Benson MD, Cruz DE, Ngo D, Deng S, Shi X, Zheng S, Eisman AS, Farrell L, Hall ME, Correa A, Tracy RP, Durda P, Taylor KD, Liu Y, Johnson WC, Guo X, Yao J, Chen YI, Manichaikul AW, Ruberg FL, Blaner WS, Jain D, Bouchard C, Sarzynski MA, Rich SS, Rotter JI, Wang TJ, Wilson JG, Clish CB, Natarajan P, Gerszten RE. Whole Genome Association Study of the Plasma Metabolome Identifies Metabolites Linked to Cardiometabolic Disease in Black Individuals. Nat Commun. 2022 08 22; 13(1):4923. PMID: 35995766; PMCID: PMC9395431; DOI: 10.1038/s41467-022-32275-3;
     
  6. Schwartz B, Schou M, Ruberg FL, Rucker D, Choi J, Siddiqi O, Monahan K, Køber L, Gislason G, Torp-Pedersen C, Andersson C. Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study. JACC CardioOncol. 2022 Sep; 4(3):313-322. PMID: 36213365; PMCID: PMC9537076; DOI: 10.1016/j.jaccao.2022.05.009;
     
  7. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
     
  8. Poterucha TJ, Kurian D, Raiszadeh F, Teruya S, Elias P, Kogan R, Chiuzan C, Einstein AJ, Ruberg FL, Maurer MS. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study). Am J Cardiol. 2022 Aug 15; 177:116-120. PMID: 35705430
     
  9. Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, Kataria S, Lohrmann G, Pipilas AR, Ruberg FL. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022 Jun; 29(2):71-78.View Related Profiles. PMID: 35083944; PMCID: PMC9258521; DOI: 10.1080/13506129.2021.2000388;
     
  10. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022 01 25; 327(4):331-340.View Related Profiles. PMID: 35076665; PMCID: PMC8790664; DOI: 10.1001/jama.2021.24110;
     
Showing 10 of 109 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 109 publications over 23 distinct years, with a maximum of 11 publications in 2017 and 2019

YearPublications
19961
19981
20011
20022
20041
20052
20063
20073
20083
20092
20104
20115
20124
20133
20143
20155
20166
201711
20189
201911
20209
202110
202210
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloidosis
Cardiac-Gated Imaging Techniques
echocardiography
MRI

Dr. Ruberg is Associate Chief of Cardiovascular Medicine for Academic Affairs and Director, Pilot Grants Program, BU Clinical and Translational Science Program. He is Associate Professor of Medicine and Radiology at Boston University School of Medicine. Dr. Ruberg is also Associate Program Director of the Cardiovascular Medicine Fellowship Training Program. An active clinical cardiologist and clinical investigator, Dr. Ruberg’s commitment to interdisciplinary research and team science is exemplified by his various responsibilities at BUMC. He is the Director of the Advanced Cardiac Imaging Program at Boston Medical Center – a clinical service involving clinicians and trainees in the Departments of Radiology and Medicine. His clinical interest is in infiltrative cardiomyopathy and he is a participating clinician and researcher in the multi-disciplinary BU/BMC Amyloidosis Center and Sarcoidosis Center. He is an internationally recognized expert in cardiac amyloidosis. His clinical and research expertise is in the field of cardiac imaging with interest in refining quantitative techniques for application in the clinical care of infiltrative cardiomyopathies. His research has been funded by the American Heart Association (AHA), Amyloidosis Foundation, industry, and NIH. Research collaboration include investigators in Boston, elsewhere in the US, and world-wide. Dr. Ruberg has served as Associate Editor of Circulation: Cardiovascular Imaging since 2016. He is a fellow of the American College of Cardiology and the American Heart Association. Dr. Ruberg is an active mentor of Internal Medicine residents and Cardiovascular Medicine fellows, having been awarding the 2017 Research Mentor of the year award from the IM residency. He serves on the Executive Committee of the newly funded NIH/NHLBI R38 award (Vasan Ramchandran, MD, PI) research in residency/StARR designed to facilitate research experiences for MD-trained IM residents.



Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

75 E. Newton St Collamore Building
Boston MA 02118
Google Map


Ruberg's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department